A study of the changes in the level of serum IgG4 antibody and soluble CD23 (s-CD23) in nasal allergy patients with immunotherapy

Auris Nasus Larynx. 1993;20(3):185-96. doi: 10.1016/s0385-8146(12)80168-4.

Abstract

Specific IgG4 antibodies were determined by enzyme-linked immunosorbent assay (ELISA), radio allergosorbent test (RAST), and s-CD23 in a total of 17 patients with nasal allergy who were given immunotherapy with house dust. The following results were obtained. 1) From the results between the serum antigen-specific IgG4 and the clinical effect of immunotherapy, there are many cases showing the elevation of antigen-specific IgG4 antibody titer. But in the elevated cases, there were only 7 cases showing good and excellent responses in a clinical effect of 41.1%. 2) IgG4 antibody was gradually elevated in many cases during immunotherapy, but in a few cases, abruptly increased after the maximum tolerated dose was established. 3) Regarding the outcome between IgG4 antibody and IgE antibody, cases of rising IgG4 and decreasing IgE occurred at a rate of 41%. 4) s-CD23 in sera gradually decreased in many cases during immunotherapy, but in a few cases, did not change.

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Antigens / immunology
  • Antigens / therapeutic use
  • Child
  • Desensitization, Immunologic*
  • Female
  • Humans
  • Immunoglobulin E / blood
  • Immunoglobulin G / blood*
  • Male
  • Mites / immunology
  • Receptors, IgE / analysis*
  • Rhinitis, Allergic, Perennial / immunology*
  • Rhinitis, Allergic, Perennial / therapy

Substances

  • Antigens
  • Immunoglobulin G
  • Receptors, IgE
  • Immunoglobulin E